Addressing barriers to initiation of insulin in patients with type 2 diabetes.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20394886.
- Also identified by DOI 10.1016/S1751-9918(10)60004-6.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Type 2 diabetes is progressive in nature and many people with the condition will inevitably require insulin therapy to attain and maintain adequate glycaemic control. In clinical practice, insulin initiation is delayed in many patients who would benefit from such treatment. Patients' and physicians' beliefs and perceptions regarding insulin therapy are known to create barriers contributing to the delay in its initiation. This article explores the nature of these barriers and offers suggestions and practical solutions for addressing and overcoming these hurdles so that insulin can be initiated confidently and appropriately in order to improve diabetes care.
Medical subject headings
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Insulin
- Patient Acceptance of Health Care
- Practice Patterns, Physicians'